Navigation Links
Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
Date:5/12/2010

SEATTLE, May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference taking place in London on May 16-18, 2010.

Dr. Kirkman will present at 10:15 a.m. British Summer Time (5:15 a.m. Eastern Daylight Time) on Tuesday, May 18 at the Grosvenor House Hotel. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon reports full year and fourth quarter 2009 financial results
2. Oncothyreon reports first quarter 2010 financial results
3. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
4. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
5. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
6. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
7. Oncothyreon announces webcast of third quarter 2009 financial results conference call
8. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
9. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
10. Oncothyreon reports second quarter 2009 financial results
11. Oncothyreon announces closing of $15.0 million registered direct financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... Common Lisp (CL) development tools, and market leader for Semantic Graph Database ... enhancements now available within the most effective system for developing and deploying applications ...
(Date:4/25/2017)... SEATTLE, WA (PRWEB) , ... April 25, 2017 , ... ... technology division of Quorum, will be featured in multiple sessions at this week’s ... range from emerging trends to best practices in clinical research. , "We are excited ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of ... round funding to three startups through the UConn Innovation Fund. The $1.5 million ... startups affiliated with UConn. , The UConn Innovation Fund provides investments of up ...
(Date:4/20/2017)... ... April 20, 2017 , ... As part of ... explore challenging patient cases when screening for direct oral anticoagulant. When patients taking ... need for bridging parental anticoagulation especially for those at high risk of thrombosis ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
Breaking Biology News(10 mins):